Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
November 22, 2024 12:12 PM 2 min read

Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook

by Nabaparna Bhattacharya Benzinga Editor
Follow

Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announced it was withdrawing its proposal to acquire Evotec SE (NASDAQ:EVO) for 11 euro ($11.44) per share in cash, implying a fully diluted equity value of 2.0 billion euro.

This move comes after prolonged efforts to engage with Evotec, which expressed its desire to remain independent, Halozyme said.

In addition to this, Halozyme reaffirmed its strong business outlook, with its 2024 guidance signaling continued growth.

The company expects revenue between $970 million and $1.02 billion ($1.003 billion) and an adjusted EBITDA range of $595 million to $625 million, reflecting significant double-digit growth.

Halozyme is confident in its ability to execute its strategy, with the goal of achieving ten approved products with ENHANZE by 2025 and $1 billion in royalty revenue by 2027.

Also Read: US Business Activity Soars To 31-Month Highs In November: Small Caps Rally, Dow Tops 44,000

Helen Torley, CEO of Halozyme, explained that although the merger would have created a leading global pharma services company, Evotec was not open to further discussions.

Halozyme’s efforts to engage with Evotec’s leadership, including multiple requests for meetings, were unsuccessful, leading to the decision to withdraw the offer.

“A company spokesperson has publicly commented that its goal is to remain an independent company,” said Helen Torley, president and chief executive officer of Halozyme regarding Evotec, adding that “our multiple requests to meet were not accepted”.

“Evotec has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Evotec for EUR11.00 per share in cash,” Evotec said in a response.

Price Action: HALO shares are trading higher by 6.21% to $48.54 at last check Friday, while EVO shares are down 18.8% to $4.345.

Photo via Shutterstock

Read Next:

  • 2025 US Economy Outlook’ Cloudier Than Normal,’ JPMorgan Says: Boom, Bust Scenarios
Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
EquitiesNewsMarketsMoversGeneralBriefsStories That Matterwhy it's moving
EVO Logo
EVOEvotec SE
$3.625.54%
Overview
HALO Logo
HALOHalozyme Therapeutics Inc
$80.194.25%
EVO Logo
EVOEvotec SE
$3.625.54%
Overview
HALO Logo
HALOHalozyme Therapeutics Inc
$80.194.25%
Comments
Loading...